Ge Healthcare Technologies Inc. (GEHC)
NASDAQ:GEHC
Want to see GEHC full AI Analyst Report?
Top Page
GE Healthcare Technologies Inc
(NASDAQ:GEHC)
Select Model
Select Model
Rating:58Neutral
Price Target:
$66.00
▼(-11.60% Downside)
Action:Reiterated
Date:05/12/26
The score is held back primarily by weak technicals (stock below major moving averages with negative MACD) and only moderate financial performance given softer TTM margins/FCF and leverage. Earnings-call takeaways are mixed—strong backlog and maintained revenue guidance offset by reduced EPS guidance and near-term cost/tariff headwinds—while valuation is fair but not compelling with a minimal dividend yield.
Positive Factors
Strong Backlog & Order Cover
A $21.8B record backlog and 1.07x book-to-bill provide durable revenue visibility across quarters, smoothing capital-equipment cyclicality. This backlog supports predictable service, upgrades and consumable demand, underpinning medium-term revenue and cash flow conversion.
Negative Factors
Moderate Leverage
Debt near parity with equity limits financial flexibility for M&A, R&D spend or cyclical shocks. For a healthcare tech company, elevated leverage raises refinancing and covenant risk and reduces room to opportunistically invest if operating margins soften.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Backlog & Order Cover
A $21.8B record backlog and 1.07x book-to-bill provide durable revenue visibility across quarters, smoothing capital-equipment cyclicality. This backlog supports predictable service, upgrades and consumable demand, underpinning medium-term revenue and cash flow conversion.
Read all positive factors
GE Healthcare Technologies Inc Key Performance Indicators (KPIs)
Any
Remaining Performance Obligations by Type
Represents the value of contracted work yet to be completed, indicating future revenue streams and the company's ability to secure long-term commitments.
Represents the value of contracted work yet to be completed, indicating future revenue streams and the company's ability to secure long-term commitments.
Data provided by:
The Fly
The FlyGE Healthcare Technologies Inc (GEHC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.98B
Dividend Yield0.17%
Average Volume (3M)5.36M
Price to Earnings (P/E)20.9
Beta (1Y)1.26
Revenue Growth5.97%
EPS Growth-12.36%
CountryUS
Employees53,000
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)3.30
Shares Outstanding454,891,780
10 Day Avg. Volume5,374,906
30 Day Avg. Volume5,356,480
Financial Highlights & Ratios
PEG Ratio4.13
Price to Book (P/B)3.61
Price to Sales (P/S)1.82
P/FCF Ratio24.86
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue1.88
Enterprise Value/Gross Profit4.42
Enterprise Value/Ebitda11.83
Forecast
1Y Price Target
$80.10Price Target Upside7.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)4.9
Revenue Forecast (FY)$21.80B
GE Healthcare Technologies Inc Business Overview & Revenue Model
Company Description
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, th...
How the Company Makes Money
GEHC primarily makes money by selling and supporting healthcare technology used in clinical settings. Key revenue streams include: (1) Equipment and system sales: one-time sales of capital equipment such as imaging systems (e.g., CT, MRI, X-ray), ...
GE Healthcare Technologies Inc Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Neutral
The call balanced encouraging top-line execution, product/regulatory milestones, a record backlog and strategic progress (Flyrcado ramp, Photonova approvals, Intelerad acquisition, organizational realignment) against meaningful near-term profitability headwinds from supplier issues, tariffs and material inflation (~$250M gross impact). Management maintained revenue guidance but prudently reduced earnings guidance and emphasized mitigation actions whose benefits are weighted to the back half of 2026. The tone was confident on medium-term growth while realistic on near-term margin pressure.Positive Updates
Top-Line Growth and Revenue Beat
Q1 revenue of $5.1B, +2.9% organic YoY, came in at the high end of guidance; product and service revenues showed strong reported growth of +7.3% and +7.5% respectively.
Negative Updates
Margin and EPS Pressure in Q1
Adjusted EBIT margin declined ~150 bps YoY to 13.5%; adjusted EPS of $0.99 was below expectations and included roughly $0.16 of tariff impact.
Read all updates
Q1-2026 Updates
Positive
Negative
Top-Line Growth and Revenue Beat
Q1 revenue of $5.1B, +2.9% organic YoY, came in at the high end of guidance; product and service revenues showed strong reported growth of +7.3% and +7.5% respectively.
Read all positive updates
Company Guidance
GE HealthCare maintained revenue guidance of 3%–4% organic sales growth (Q2 also guided 3%–4%), expects an approximate 100-basis-point FX tailwind to revenue, and set full-year adjusted EBIT margin at 15.4%–15.7% (up ~10–40 bps year‑over‑year) with adjusted EPS now $4.80–$5.00 (≈5%–9% growth YoY, and a low‑single‑digit EPS decline expected in Q2); management called out a gross inflation headwind of roughly $250 million (~$0.43/share) — driven by about $100M memory chips, $100M oil/freight and ~$50M metals/other — of which they expect to offset more than half via price and cost actions (they reduced EPS by $0.15 for the remaining inflation effect), expect tariffs to be lower than 2025 (Q1 contained the largest tariff hit and adjusted EPS included ~ $0.16 of tariff impact), and now forecast free cash flow of approximately $1.6 billion (supported by a 1.07x book‑to‑bill and a record $21.8 billion backlog).GE Healthcare Technologies Inc Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
64
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.95B | 20.63B | 19.67B | 19.55B | 18.34B | 17.59B |
| Gross Profit | 8.49B | 8.25B | 8.21B | 7.92B | 7.18B | 7.17B |
| EBITDA | 3.17B | 3.79B | 3.67B | 3.51B | 3.17B | 3.54B |
| Net Income | 1.50B | 2.08B | 1.99B | 1.57B | 1.92B | 2.25B |
Balance Sheet | ||||||
| Total Assets | 37.13B | 36.91B | 33.09B | 32.45B | 27.54B | 26.31B |
| Cash, Cash Equivalents and Short-Term Investments | 2.29B | 4.51B | 2.89B | 2.50B | 1.45B | 556.00M |
| Total Debt | 10.58B | 10.00B | 9.38B | 9.86B | 8.63B | 437.00M |
| Total Liabilities | 26.23B | 26.31B | 24.44B | 25.14B | 17.95B | 9.41B |
| Stockholders Equity | 10.67B | 10.38B | 8.45B | 7.13B | 9.36B | 16.66B |
Cash Flow | ||||||
| Free Cash Flow | 1.52B | 1.51B | 1.55B | 1.71B | 1.80B | 1.36B |
| Operating Cash Flow | 2.03B | 1.99B | 1.95B | 2.10B | 2.11B | 1.61B |
| Investing Cash Flow | -3.14B | -1.05B | -914.00M | -558.00M | -398.00M | -1.76B |
| Financing Cash Flow | 924.00M | 617.00M | -573.00M | -478.00M | -822.00M | -263.00M |
GE Healthcare Technologies Inc Technical Analysis
Negative
74.66
Price Trends
68.52
Negative
75.13
Negative
75.58
Negative
Market Momentum
-2.48
Negative
38.40
Neutral
20.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GEHC, the sentiment is Negative. The current price of 74.66 is above the 20-day moving average (MA) of 63.57, above the 50-day MA of 68.52, and below the 200-day MA of 75.58, indicating a bearish trend. The MACD of -2.48 indicates Negative momentum. The RSI at 38.40 is Neutral, neither overbought nor oversold. The STOCH value of 20.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GEHC.
GE Healthcare Technologies Inc Risk Analysis
GE Healthcare Technologies Inc disclosed 32 risk factors in its most recent earnings report. GE Healthcare Technologies Inc reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GE Healthcare Technologies Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $7.02B | 37.09 | 10.11% | ― | 9.47% | 124.24% | |
75 Outperform | $26.74B | 34.31 | 13.41% | ― | 16.34% | 25.89% | |
73 Outperform | $3.62B | 22.23 | 19.36% | ― | 13.05% | -12.34% | |
73 Outperform | $4.23B | 21.58 | -138.70% | ― | 49.78% | -484.05% | |
58 Neutral | $27.98B | 20.86 | 14.77% | 0.17% | 5.97% | -12.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $7.83B | -16.06 | -70.24% | ― | 69.82% | 62.77% |
* Healthcare Sector Average
GEHC
GE Healthcare Technologies Inc
64.26
-5.19
-7.48%
VEEV
Veeva Systems
164.96
-70.04
-29.80%
HQY
Healthequity
87.55
-11.25
-11.38%
DOCS
Doximity
19.86
-30.89
-60.87%
TEM
Tempus AI, Inc. Class A
45.88
-12.26
-21.09%
HNGE
Hinge Health, Inc. Class A
54.74
14.58
36.30%
GE Healthcare Technologies Inc Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
GE HealthCare shareholders back board, governance and compensation
Positive
May 11, 2026
At its annual meeting of stockholders held on May 7, 2026, GE HealthCare Technologies Inc. shareholders elected eight directors to one-year terms ending at the 2027 annual meeting and gave advisory approval to the company’s executive compens...
Executive/Board Changes
GE HealthCare Announces Board Changes and New Director Appointment
Neutral
Mar 17, 2026
On March 13, 2026, GE HealthCare Technologies Inc. appointed Kevin A. Lobo to its Board of Directors, with his term running until the 2026 Annual Meeting of Stockholders, and named him to the Talent, Culture, and Compensation Committee, with compe...
Business Operations and StrategyPrivate Placements and Financing
GE HealthCare Establishes New 364-Day Revolving Credit Facility
Neutral
Feb 27, 2026
On February 26, 2026, GE HealthCare Technologies Inc. entered into a new 364-day senior unsecured revolving credit agreement with JPMorgan Chase Bank and a syndicate of lenders, establishing a $0.5 billion committed facility that matures on Februa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.